Genital Diseases, Female  >>  Erivedge (vismodegib)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Erivedge (vismodegib) / Roche
NCT00739661 / 2008-003789-24: A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) As Maintenance Therapy in Patients With Ovarian Cancer in a Second or Third Complete Remission

Completed
2
104
NA
Vismodegib 150 mg, GDC-0449, Placebo to vismodegib
Genentech, Inc.
Ovarian Cancer
11/10
11/10

Download Options